{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T14:51:25Z","timestamp":1782399085145,"version":"3.54.5"},"reference-count":51,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"unspecified","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron","doi-asserted-by":"crossref","award":["R668-ONC-1845"],"award-info":[{"award-number":["R668-ONC-1845"]}],"id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R21 CA280445"],"award-info":[{"award-number":["R21 CA280445"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009419","name":"Cutaneous Lymphoma Foundation","doi-asserted-by":"publisher","award":["R21 CA280445"],"award-info":[{"award-number":["R21 CA280445"]}],"id":[{"id":"10.13039\/100009419","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,5,16]]},"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Limited therapeutic options are available for patients with advanced-stage mycosis fungoides (MF), and the 5-year survival rate is 25%. Due to its critical role in MF pathogenesis, the IL4\/IL13 pathway presents a promising target for treatment. Here, we analyzed blocking of IL4R\u03b1, the common subunit of the IL4 and IL13 receptors, within the advanced-stage MF cutaneous tumor microenvironment (TME).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Cellular Indexing of Transcriptomes and Epitopes by sequencing was employed to assess the transcriptional profile of the cells expressing the IL4 and IL13 receptors within the advanced MF TME. We combined IL4R\u03b1 inhibition by REGN668 (dupilumab) in ex vivo skin explants from advanced MF patients with single-cell transcriptome and machine learning analysis to identify the molecular mechanisms of IL4R\u03b1 signaling within the MF skin lesions. Parallel analysis of the T cell immune repertoire allowed identification of the expanded malignant clone within each MF sample. Multicolor immunofluorescence microscopy was employed to validate molecular findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      REGN668 inhibits patient-specific processes in malignant lymphocytes; however, we also identified downregulation of common pathways among patient samples, including those associated with cell cycle progression, PI3K\/AKT signaling, janus kinase (JAK)\/Signal Transducer and Activator of Transcription (STAT) signaling, DNA damage\/repair, and TP53 regulation. Furthermore, we showed that IL4R\u03b1 blockade in the TME of advanced MF downregulates multiple immunosuppressive pathways associated with myeloid-derived suppressor cells and LAMP3\n                      <jats:sup>+<\/jats:sup>\n                      dendritic cell recruitment and function, cytokine production, and antigen presentation in B cells, as well as differentiation and degranulation of mast cells.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These results provide new insights into advanced MF tumorigenesis and show that the effects of IL4R\u03b1 blockade are specific to the STAT6 pathway, inhibiting proliferation of malignant lymphocytes, as well as repressing several immunosuppressive mechanisms within the MF TME. However, the extensive genetic, transcriptional, and functional heterogeneity across MF patients indicates that inhibition of multiple driver pathways and a personalized therapeutic approach will be important for developing new therapeutic strategies against this disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2026-015022","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T14:25:29Z","timestamp":1782397529000},"page":"e015022","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["IL4R\u03b1 blockade inhibits proliferation of malignant lymphocytes and the immunosuppressive tumor microenvironment of mycosis fungoides"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8606-2204","authenticated-orcid":false,"given":"Alyxzandria M","family":"Gaydosik","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8246-6697","authenticated-orcid":false,"given":"Alyson","family":"Wang","sequence":"additional","affiliation":[{"name":"Center for Systems Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5747-064X","authenticated-orcid":false,"given":"Jishnu","family":"Das","sequence":"additional","affiliation":[{"name":"Center for Systems Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigit","family":"Lapolla","sequence":"additional","affiliation":[{"name":"Columbia University Medical Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1339-5710","authenticated-orcid":false,"given":"Oleg E","family":"Akilov","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa J","family":"Geskin","sequence":"additional","affiliation":[{"name":"Columbia University Medical Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1051-5262","authenticated-orcid":false,"given":"Patrizia","family":"Fuschiotti","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"2026062507251747000_14.6.e015022.1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"2026062507251747000_14.6.e015022.2","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030746","article-title":"Mycosis Fungoides and S\u00e9zary Syndrome: Microenvironment and Cancer Progression","volume":"15","author":"Dobos","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026062507251747000_14.6.e015022.3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-611830"},{"key":"2026062507251747000_14.6.e015022.4","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3389\/fmed.2019.00116","article-title":"Novel and Future Therapeutic Drugs for Advanced Mycosis Fungoides and S\u00e9zary Syndrome","volume":"6","author":"Oka","year":"2019","journal-title":"Front Med"},{"key":"2026062507251747000_14.6.e015022.5","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1158\/1078-0432.CCR-21-4437","article-title":"Single-Cell RNA Sequencing Unveils the Clonal and Transcriptional Landscape of Cutaneous T-Cell Lymphomas","volume":"28","author":"Gaydosik","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026062507251747000_14.6.e015022.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-024-02018-1"},{"key":"2026062507251747000_14.6.e015022.7","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-28799-3","article-title":"Single-cell transcriptomics links malignant T cells to the tumor immune landscape in cutaneous T cell lymphoma","volume":"13","author":"Liu","year":"2022","journal-title":"Nat Commun"},{"key":"2026062507251747000_14.6.e015022.8","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.170015","article-title":"The mycosis fungoides cutaneous microenvironment shapes dysfunctional cell trafficking, antitumor immunity, matrix interactions, and angiogenesis","volume":"8","author":"Gaydosik","year":"2023","journal-title":"JCI Insight"},{"key":"2026062507251747000_14.6.e015022.9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-590398"},{"key":"2026062507251747000_14.6.e015022.10","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004725"},{"key":"2026062507251747000_14.6.e015022.11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013379"},{"key":"2026062507251747000_14.6.e015022.12","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16050861","article-title":"JAK Inhibitors in Cutaneous T-Cell Lymphoma: Friend or Foe? A Systematic Review of the Published Literature","volume":"16","author":"Vahabi","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026062507251747000_14.6.e015022.13","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2147\/JAA.S52387","article-title":"Dupilumab: a novel treatment for asthma","volume":"7","author":"Vatrella","year":"2014","journal-title":"J Asthma Allergy"},{"key":"2026062507251747000_14.6.e015022.14","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s40257-025-00955-7","article-title":"Cutaneous T Cell Lymphoma Following Dupilumab Therapy in Patients with Atopic Dermatitis: Clinical Review and Recommendations","volume":"26","author":"Lavin","year":"2025","journal-title":"Am J Clin Dermatol"},{"key":"2026062507251747000_14.6.e015022.15","doi-asserted-by":"crossref","first-page":"102563","DOI":"10.1016\/j.coi.2025.102563","article-title":"Dupilumab-associated lymphoproliferative disorders: a comprehensive review on clinicohistopathologic features and underlying mechanisms","volume":"94","author":"Li","year":"2025","journal-title":"Curr Opin Immunol"},{"key":"2026062507251747000_14.6.e015022.16","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/j.jaci.2024.10.028","article-title":"Integrative epidemiology and immunotranscriptomics uncover a risk and potential mechanism for cutaneous lymphoma unmasking or progression with dupilumab therapy","volume":"155","author":"Cabrera-Perez","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"2026062507251747000_14.6.e015022.17","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1007\/s00403-023-02652-z","article-title":"Dupilumab-associated mycosis fungoides: a cross-sectional study","volume":"315","author":"Hamp","year":"2023","journal-title":"Arch Dermatol Res"},{"key":"2026062507251747000_14.6.e015022.18","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/s41592-024-02175-z","article-title":"SLIDE: Significant Latent Factor Interaction Discovery and Exploration across biological domains","volume":"21","author":"Rahimikollu","year":"2024","journal-title":"Nat Methods"},{"key":"2026062507251747000_14.6.e015022.19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-881268"},{"key":"2026062507251747000_14.6.e015022.20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.7142"},{"key":"2026062507251747000_14.6.e015022.21","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1158\/2326-6066.CIR-25-0677","article-title":"IL4\/IL13 Inhibition via Dupilumab Reduces Malignant T-cell Proliferation and Promotes Antitumor Immunity in S\u00e9zary Syndrome","volume":"14","author":"Geskin","year":"2026","journal-title":"Cancer Immunol Res"},{"key":"2026062507251747000_14.6.e015022.22","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3192"},{"key":"2026062507251747000_14.6.e015022.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.05.031"},{"key":"2026062507251747000_14.6.e015022.24","doi-asserted-by":"publisher","DOI":"10.1016\/J.CELL.2021.04.048"},{"key":"2026062507251747000_14.6.e015022.25","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.4380"},{"key":"2026062507251747000_14.6.e015022.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.05.002"},{"key":"2026062507251747000_14.6.e015022.27","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1214\/15-AOS1337","article-title":"Controlling the false discovery rate via knockoffs","volume":"43","author":"Barber","year":"2015","journal-title":"Ann Statist"},{"key":"2026062507251747000_14.6.e015022.28","doi-asserted-by":"crossref","DOI":"10.1016\/j.patter.2022.100473","article-title":"Essential Regression: A generalizable framework for inferring causal latent factors from multi-omic datasets","volume":"3","author":"Bing","year":"2022","journal-title":"Patterns (N Y)"},{"key":"2026062507251747000_14.6.e015022.29","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btt703"},{"key":"2026062507251747000_14.6.e015022.30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01147"},{"key":"2026062507251747000_14.6.e015022.31","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.930979","article-title":"Mast cells and tryptase are linked to itch and disease severity in mycosis fungoides: Results of a pilot study","volume":"13","author":"Terhorst-Molawi","year":"2022","journal-title":"Front Immunol"},{"key":"2026062507251747000_14.6.e015022.32","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004256"},{"key":"2026062507251747000_14.6.e015022.33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-802470"},{"key":"2026062507251747000_14.6.e015022.34","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009655"},{"key":"2026062507251747000_14.6.e015022.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.06.006"},{"key":"2026062507251747000_14.6.e015022.36","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2319994121","article-title":"NRF2 is a spatiotemporal metabolic hub essential for the polyfunctionality of Th2 cells","volume":"121","author":"Choi","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026062507251747000_14.6.e015022.37","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14112603","article-title":"Tumor Necrosis Factor Receptor 2 (TNFR2): An Emerging Target in Cancer Therapy","volume":"14","author":"Medler","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026062507251747000_14.6.e015022.38","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-019-0344-8"},{"key":"2026062507251747000_14.6.e015022.39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-056010"},{"key":"2026062507251747000_14.6.e015022.40","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0310"},{"key":"2026062507251747000_14.6.e015022.41","doi-asserted-by":"crossref","DOI":"10.1186\/s12964-024-01655-1","article-title":"Conversion of dendritic cells into tolerogenic or inflammatory cells depends on the activation threshold and kinetics of the mTOR signaling pathway","volume":"22","author":"Wixler","year":"2024","journal-title":"Cell Commun Signal"},{"key":"2026062507251747000_14.6.e015022.42","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jid.2019.08.454","article-title":"Preclinical Evidence for Targeting PI3K\/mTOR Signaling with Dual-Inhibitors as a Therapeutic Strategy against Cutaneous T-Cell Lymphoma","volume":"140","author":"Bresin","year":"2020","journal-title":"J Invest Dermatol"},{"key":"2026062507251747000_14.6.e015022.43","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/ijc.28546","article-title":"Overexpression of hypoxia-inducible factor 1 alpha impacts FoxP3 levels in mycosis fungoides--cutaneous T-cell lymphoma: clinical implications","volume":"134","author":"Alc\u00e1ntara-Hern\u00e1ndez","year":"2014","journal-title":"Int J Cancer"},{"key":"2026062507251747000_14.6.e015022.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.02.017"},{"key":"2026062507251747000_14.6.e015022.45","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/eji.202049043","article-title":"CCR4 in cutaneous T-cell lymphoma: Therapeutic targeting of a pathogenic driver","volume":"51","author":"Nicolay","year":"2021","journal-title":"Eur J Immunol"},{"key":"2026062507251747000_14.6.e015022.46","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30379-6"},{"key":"2026062507251747000_14.6.e015022.47","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-024-02096-7","article-title":"Cellular senescence and SASP in tumor progression and therapeutic opportunities","volume":"23","author":"Dong","year":"2024","journal-title":"Mol Cancer"},{"key":"2026062507251747000_14.6.e015022.48","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s12016-019-08753-w","article-title":"Role of Mast Cells in Shaping the Tumor Microenvironment","volume":"58","author":"Komi","year":"2020","journal-title":"Clinic Rev Allerg Immunol"},{"key":"2026062507251747000_14.6.e015022.49","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-415638"},{"key":"2026062507251747000_14.6.e015022.50","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2012.00143","article-title":"The SNARE Machinery in Mast Cell Secretion","volume":"3","author":"Lorentz","year":"2012","journal-title":"Front Immunol"},{"key":"2026062507251747000_14.6.e015022.51","doi-asserted-by":"publisher","DOI":"10.4161\/15384101.2014.965061"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2026-015022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T14:25:33Z","timestamp":1782397533000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2026-015022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":51,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,25]]},"published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1136\/jitc-2026-015022"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2026-015022","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]}}}